Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion (28) Apply Summaries of opinion filter Orphan designations (259) Apply Orphan designations filter Referrals (18) Apply Referrals filter Direct healthcare professional communication (42) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (8) Apply Yes filter

Authorisation status

Authorised (451) Apply Authorised filter Refused (19) Apply Refused filter Withdrawn (67) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (54) Apply Initial authorisation filter Post-authorisation (12) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (21) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (195) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (2) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (38) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (42) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Orphan medicine Remove Orphan medicine filter Generic (347) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

861 results

Remove all filtersRemove all filters

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Medicine type Exceptional circumstances Remove Exceptional circumstances filter Orphan medicine Remove Orphan medicine filter Conditional approval Remove Conditional approval filter Biosimilar Remove Biosimilar filter Accelerated assessment Remove Accelerated assessment filter Additional monitoring Remove Additional monitoring filter

Medicine European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Withdrawn applications Remove Withdrawn applications filter

Sort by

List item

Human medicine European public assessment report (EPAR): Xevudy (updated)

Sotrovimab, COVID-19 virus infection
Date of authorisation: 17/12/2021, , Revision: 9, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Pandemic Influenza Vaccine H5N1 Baxter AG (updated)

influenza vaccine (whole virion, inactivated) containing antigen of: A/Vietnam/1203/2004 (H5N1), Influenza, Human; Immunization; Disease Outbreaks
Date of authorisation: 16/10/2009, , Revision: 8, Withdrawn, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Beovu (updated)

brolucizumab, Wet Macular Degeneration
Date of authorisation: 13/02/2020, , Revision: 10, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene) (updated)

Pomalidomide, Multiple Myeloma
Date of authorisation: 05/08/2013, , Revision: 24, Authorised, Last updated: 13/09/2023
List item

Human medicine European public assessment report (EPAR): Mektovi (updated)

binimetinib, Melanoma
Date of authorisation: 20/09/2018, , Revision: 7, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Roctavian (updated)

valoctocogene roxaparvovec,
Date of authorisation: 24/08/2022, , , , Revision: 3, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Evrysdi (updated)

Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021, , Revision: 4, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Pemazyre (updated)

pemigatinib, Cholangiocarcinoma
Date of authorisation: 26/03/2021, , , , Revision: 6, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Ogivri (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 12/12/2018, , Revision: 10, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Vegzelma (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022, , , Revision: 4, Authorised, Last updated: 12/09/2023
List item

Human medicine European public assessment report (EPAR): Ledaga (updated)

Chlormethine, Mycosis Fungoides
Date of authorisation: 03/03/2017, , Revision: 9, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Comirnaty (updated)

Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2, COVID-19 virus infection
Date of authorisation: 21/12/2020, , , Revision: 44, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Tremelimumab AstraZeneca (updated)

Tremelimumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 20/02/2023, , Revision: 1, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Benlysta (updated)

belimumab, Lupus Erythematosus, Systemic
Date of authorisation: 13/07/2011, , Revision: 31, Authorised, Last updated: 11/09/2023
List item

Human medicine European public assessment report (EPAR): Imjudo (updated)

Tremelimumab, Carcinoma, Hepatocellular
Date of authorisation: 20/02/2023, , Revision: 1, Authorised, Last updated: 08/09/2023
List item

Human medicine European public assessment report (EPAR): Hulio (updated)

adalimumab, Hidradenitis Suppurativa; Psoriasis; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
Date of authorisation: 17/09/2018, , Revision: 15, Authorised, Last updated: 08/09/2023
List item

Human medicine European public assessment report (EPAR): Natpar (updated)

parathyroid hormone, Hypoparathyroidism
Date of authorisation: 24/04/2017, , , , Revision: 16, Authorised, Last updated: 08/09/2023
List item

Human medicine European public assessment report (EPAR): Emgality (updated)

Galcanezumab, Migraine Disorders
Date of authorisation: 14/11/2018, , Revision: 10, Authorised, Last updated: 07/09/2023
List item

Human medicine European public assessment report (EPAR): Nepexto (updated)

etanercept, Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Arthritis, Psoriatic; Spondylarthropathies; Spondylitis, Ankylosing; Psoriasis
Date of authorisation: 20/05/2020, , , Revision: 10, Authorised, Last updated: 07/09/2023
List item

Human medicine European public assessment report (EPAR): Poteligeo (updated)

Mogamulizumab, Sezary Syndrome; Mycosis Fungoides
Date of authorisation: 22/11/2018, , Revision: 6, Authorised, Last updated: 06/09/2023
List item

Human medicine European public assessment report (EPAR): Voxzogo (updated)

Vosoritide, Achondroplasia
Date of authorisation: 26/08/2021, , , Revision: 3, Authorised, Last updated: 06/09/2023
List item

Human medicine European public assessment report (EPAR): Ninlaro (updated)

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , , , Revision: 16, Authorised, Last updated: 05/09/2023
List item

Human medicine European public assessment report (EPAR): Rekambys (updated)

rilpivirine, HIV Infections
Date of authorisation: 17/12/2020, , Revision: 8, Authorised, Last updated: 05/09/2023
List item

Human medicine European public assessment report (EPAR): Ziextenzo (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 22/11/2018, , Revision: 8, Authorised, Last updated: 05/09/2023
List item

Human medicine European public assessment report (EPAR): Skyrizi (updated)

Risankizumab, Psoriasis; Arthritis, Psoriatic
Date of authorisation: 26/04/2019, , Revision: 16, Authorised, Last updated: 04/09/2023